Acute Porphyria Drug Database

R03BA02 - Budesonide
Not porphyrinogenic
NP

Rationale
Inducer of 3A5. Probably quantitatively insignificant metabolic exposure Several references stating non-porphyrinogenicity of glucocorticoids. Significant clinical experience of non-porphyrinogenicity.
Chemical description
(To be edited, initial data ST OCT 04) Corticosteroide in inhalation aerosol (50 ug/dose)l, used in treatment of asthma. Systemic bioavailability about 26 %. Metabolized by CYP 3A4. C.Andersson, patient reports: tolerated (n=8). Used in porphyria ward (Sweden). glucocorticoids EPI-list: safe South African list: use Kalman, Bonkowski: safe The Merck Manual: safe Tschudy DP, Lamon JM: Porphyrin metabolism and the porphyrias, in Bondy PK, Rosenberg LE (eds.): Duncans Diseases of Metabolism. Philadelphia, WB Saunders, 1980, p939: safe Moore MR, Hift RJ: Drugs in the acute porphyrias. Cell Mol Biol 43:89, 1997: safe
IPNet drug reports
Uneventful use reported in 21 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes R03B / R03BA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙